Gcc2 as a new early diagnostic biomarker for non-small cell lung cancer

Hyesun Jeong, Byeong Hyeon Choi, Jina Park, Jik Han Jung, Hyunku Shin, Ka Won Kang, Yu Hua Quan, Jewon Yu, Ji Ho Park, Yong Park, Yeonho Choi, Hyun Koo Kim, Sunghoi Hong

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


No specific markers have been identified to detect non-small cell lung cancer (NSCLC) cell-derived exosomes circulating in the blood. Here, we report a new biomarker that distinguishes between cancer and non-cancer cell-derived exosomes. Exosomes isolated from patient plasmas at various pathological stages of NSCLC, NSCLC cell lines, and human pulmonary alveolar epithelial cells isolated using size exclusion chromatography were characterized. The GRIP and coiled-coil domain-containing 2 (GCC2) protein, involved in endosome-to-Golgi transport, was identified by proteomics analysis of NSCLC cell line-derived exosomes. GCC2 protein levels in the exosomes derived from early-stage NSCLC patients were higher than those from healthy controls. Receiver operating characteristic curve analysis revealed the diagnostic sensitivity and specificity of exoso-mal GCC2 to be 90% and 75%, respectively. A high area under the curve, 0.844, confirmed that GCC2 levels could effectively distinguish between the exosomes. These results demonstrate GCC2 as a promising early diagnostic biomarker for NSCLC.

Original languageEnglish
Article number5482
Issue number21
Publication statusPublished - 2021 Nov 1

Bibliographical note

Funding Information:
Funding: This research was funded by the Ministry of Health & Welfare (HR14C0007), and the Ministry of Science and ICT (2019M3E5D5065399) of the Government of the Republic of Korea.

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.


  • Biomarkers
  • Cancer
  • Early detection
  • Exosomes
  • GCC2
  • Liquid biopsy
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Gcc2 as a new early diagnostic biomarker for non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this